Our preclinical studies identified that pharmacological inhibition of both BTK and mTOR reduced the GBM cell lines CSCs’ maintenance capabilities and greatly affected HUVEC cells migration and tube formation abilities. This evidence concerns the gene MTOR and glioblastoma.